The treatment of spasticity with Δ9-tetrahydrocannabinol in persons with spinal cord injury

Spinal Cord

Volumn 45, Issue 8, 2007, Pages 551-562

  Hagenbach, U ^a   Luz, S ^a   Ghafoor, N ^a   Berger, J M ^a   Grotenhermen, F ^b   Brenneisen, R ^c   Mader M ^a  

^a REHAB Basel   (Switzerland)

^b Nova Institut   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cannabinoid; Cannabis; Pain; Spasticity; Spinal cord injury; THC

Indexed keywords

DRONABINOL; PLACEBO; TETRAHYDROCANNABINOL DERIVATIVE; TETRAHYDROCANNABINOL HEMISUCCINATE; UNCLASSIFIED DRUG; TETRAHYDROCANNABINOL;

ADULT; AGED; ANXIETY; ARTICLE; ASTHENIA; ATTENTION; ATTENTION DISTURBANCE; BLADDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOMETRY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MOOD; MOOD DISORDER; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PARALYSIS; PERCEPTION DISORDER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF CONCEPT; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SPASTICITY; SPINAL CORD INJURY; TREATMENT DURATION; UNPLEASANT SENSATION; VISUAL IMPAIRMENT; XEROSTOMIA; AFFECT; EXERCISE TEST; LUNG; MANOMETRY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RECTAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADULT; AFFECT; AGED; ATTENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; HUMANS; LUNG; MALE; MANOMETRY; MIDDLE AGED; MUSCLE SPASTICITY; NEUROPSYCHOLOGICAL TESTS; PAIN; SPINAL CORD INJURIES; TETRAHYDROCANNABINOL; TREATMENT OUTCOME; URINARY BLADDER;

EID: 34547623372     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sj.sc.3101982     Document Type: Article

References (51)

1. Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R (ed). Cannabinoids as Therapeutic Agents. CRC Press: Boca Raton.
2. Reynolds JR. Therapeutic uses and toxic effects of Cannabis indica. Lancet 1890; 1: 637-638.
3. Dunn M, Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia 1974; 12: 175.
4. Malec J, Harvey RF, Cayner JJ. Cannabis effect on spasticity in spinal cord injury. Arch Phys Med Rehabil 1982; 63: 116-118.
5. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38: 44-48.
6. Consroe P, Tillery W, Rein J, Musty RE. Reported marijuana effects in patients with spinal cord injury. 1998 Symposium on the Cannabinoids. International Cannabinoid Research Society: Burlington 1998, p 64.
7. Petro DJ. Marijuna as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980; 21: 81-85.
8. Meinck HM, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989; 236: 120-122.
9. 9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21: 413-416.
10. 9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7: 39-50.
11. Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows anti-spastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiat Clin Neurosci 1990; 240: 1-4.
12. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995; 345: 579.
13. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996; 34: 446-452.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokin 2003; 42: 327-360.
15. Pertwee RG. Sites and mechanisms of action. In: Grotenhermen F, Russo E (eds). Cannabis and Cannabinoids. Pharmacology, Toxicology, and Therapeutic Potential. Haworth Press: Binghamton NY 2002, pp 73-87.
16. Sañudo-Peña MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999; 65: 703-713.
17. Tarrico M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury (Cochrane Review). Cochrane Database Syst Rev 2000; 2: CD001131.
18. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2001; 4: CD001332.
19. Zajicek J et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-1526.
20. Zajicek J. The cannabinoids in MS study - final results from 12 months follow-up. Mult Scler 2004; 10(Suppl 2): 115.
21. Vaney C et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10: 417-424.
22. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-441.
23. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206-207.
24. Granger CV, Hamilton BB, Linacre JM, Heinemann AW, Wright BD. Performance profiles of the functional independence measure. Arch Phys Rehabil 1993; 72: 84-89.
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
26. Baker DB, Taylor CJ, Leyva C. Continious performance tests: a comparison of modalities. J Clin Psychol 1995; 51(4): 548-551.
27. Zazzo R. Test de deux barrages. Actualités pedagogiques et psychologique Vol. 7. Delachaux et Nestlé: Neuchâtel 1974.
28. Killestein J et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-1407.
29. Pertwee RG. Prescribing cannabinoids for multiple sclerosis. CNS Drugs 1999; 11: 327-334.
30. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983; 13: 669-671.
31. Helwig S, Fronk EM, Reif M, Schnelle M, Hoffmann J. Maximally tolerated dose (mtd) of standardized cannabis extract in palliative cancer patients: preliminary results from an open label, on-randomized phase I/II trial. Second Conference on Cannabis and Cannabinoids International Association Cannabis as Medicine, Cologne, September 12-13, 2003.
32. Kogel RW, Johnson PB, Chintam R, Robinson CHJ, Nemchausky BA. Treatment of spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol derivate. Am J Ther 1995; 2: 799-805.
33. Riazi A, Fox P, Vickery J, Thompson AJ, Zajicek J, Hobart JC. Developing a patient-based measure of the impact of spasticity in multiple sclerosis. Mult Scler 2003; 9: 151.
34. Noth J. Trends in the pathophysiology and pharmacotherapy of spasticity. J Neurol 1991; 238: 131-139.
35. Gilman S, Newman SW (eds). Manter and Gatz's Essentials of Clinical Neuroanatomy and Neurophysiology 9th edn. Philadelphia: FA Davis Company 1996.
36. Musty RE, Consroe P. Spastic Disorders. In: Grotenhermen F, Russo E (eds). Cannabis and Cannabinoids. Pharmacology, Toxicology, and Therapeutic Potential. Haworth Press: Binghamton NY 2002, pp 195-197.
37. Baker D et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300-302.
38. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 18-26.
39. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkely KJ, Fowler CJ. An open label pilot study of cannabis-based extracts for bladder dysfunction in advanced muliple sclerosis. Mult Scler 2004; 10: 425-433.
40. Müller-Vahl KR, Koblenz A, Jobges M, Kolbe H, Emrich HM, Schneider U. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 2001; 34: 19-24.
41. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329: 253-260.
42. Young CA, Rog DJ. Randomised controlled trial of cannabis based medicinal extracts (CBME) in central neuropathic pain due to multiple sclerosis. IV. Congress of the European Federation of IASP Chapters (EFIC) September 2-6, 2003, Prag.
43. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112: 299-306.
44. Abrams DI et al. The effects of smoked cannabis in painful peripheral neuropathy and cancer pain refractory to opioids. IACM 2nd Conference on Cannabinoids in Medicine Cologne, September 12-13, 2003.
45. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 2004; 8: 173-177.
46. Clark WC, Janal MN, Zeidenberg P, Nahas GG. Effects of moderate and high doses of marihuana on thermal pain: a sensory decision theory analysis. J Clin Pharmacol 1981; 21(8-9 Suppl): 299-310.
47. Hill SY, Schwin R, Goodwin DW, Powell B. Marihuana and pain. J Pharmacol Exp Ther 1974; 188: 415-418.
48. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003; 105: 79-88.
49. Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther 1977; 21: 26-33.
50. Jochimsen PR, Lawton RL, VerSteeg K, Noyes Jr R. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther 1978; 24: 223-227.
51. Zwillich CW, Doekel R, Hammill S, Weil JV. The effects of smoked marijuana on metabolism and respiratory control. Am Rev Respir Dis 1978; 118: 885-891.